ALBIREO PHARMA, INC. Quarterly Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest in USD from Q2 2010 to Q3 2022
-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.
-
Summary
-
Albireo Pharma, Inc. quarterly/annual Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest history and growth rate from Q2 2010 to Q3 2022.
- Albireo Pharma, Inc. Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest for the quarter ending September 30, 2022 was -$37.8M, a 162% decline year-over-year.
- Albireo Pharma, Inc. annual Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest for 2021 was -$34M, a 68.4% increase from 2020.
- Albireo Pharma, Inc. annual Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest for 2020 was -$108M, a 71.6% decline from 2019.
- Albireo Pharma, Inc. annual Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest for 2019 was -$62.7M, a 36.1% decline from 2018.
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest, Trailing 12 Months (USD)
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest, Quarterly (USD)
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest, YoY Quarterly Growth (%)